AU2004247018A1 - Novel immunomodulating peptide - Google Patents

Novel immunomodulating peptide Download PDF

Info

Publication number
AU2004247018A1
AU2004247018A1 AU2004247018A AU2004247018A AU2004247018A1 AU 2004247018 A1 AU2004247018 A1 AU 2004247018A1 AU 2004247018 A AU2004247018 A AU 2004247018A AU 2004247018 A AU2004247018 A AU 2004247018A AU 2004247018 A1 AU2004247018 A1 AU 2004247018A1
Authority
AU
Australia
Prior art keywords
nogo
peptide
antigen
sequence
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004247018A
Other languages
English (en)
Inventor
Paulo Fontoura
Hideki Garren
Lawrence Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayhill Therapeutics Inc
Leland Stanford Junior University
Original Assignee
Bayhill Therapeutics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics Inc, Leland Stanford Junior University filed Critical Bayhill Therapeutics Inc
Publication of AU2004247018A1 publication Critical patent/AU2004247018A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
AU2004247018A 2003-05-15 2004-05-14 Novel immunomodulating peptide Abandoned AU2004247018A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47059303P 2003-05-15 2003-05-15
US60/470,593 2003-05-15
PCT/US2004/015387 WO2004110353A2 (en) 2003-05-15 2004-05-14 Novel immunomodulating peptide

Publications (1)

Publication Number Publication Date
AU2004247018A1 true AU2004247018A1 (en) 2004-12-23

Family

ID=33551419

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004247018A Abandoned AU2004247018A1 (en) 2003-05-15 2004-05-14 Novel immunomodulating peptide

Country Status (7)

Country Link
US (1) US7867976B2 (cg-RX-API-DMAC10.html)
EP (1) EP1633315A4 (cg-RX-API-DMAC10.html)
JP (1) JP2007537985A (cg-RX-API-DMAC10.html)
CN (1) CN101410130A (cg-RX-API-DMAC10.html)
AU (1) AU2004247018A1 (cg-RX-API-DMAC10.html)
CA (1) CA2525966A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004110353A2 (cg-RX-API-DMAC10.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055609A1 (en) * 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6531130B1 (en) * 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth

Also Published As

Publication number Publication date
US7867976B2 (en) 2011-01-11
WO2004110353A2 (en) 2004-12-23
WO2004110353A3 (en) 2009-04-02
CA2525966A1 (en) 2004-12-23
EP1633315A4 (en) 2010-09-08
EP1633315A2 (en) 2006-03-15
CN101410130A (zh) 2009-04-15
US20070280954A1 (en) 2007-12-06
JP2007537985A (ja) 2007-12-27

Similar Documents

Publication Publication Date Title
Monneaux et al. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice
Engdahl et al. Periarticular bone loss in arthritis is induced by autoantibodies against citrullinated vimentin
US20100203053A1 (en) Method and composition for treating immune complex associated disorders
Fontoura et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis
JP2013032358A (ja) リウマチ疾患の診断方法
Seamons et al. Competition between two MHC binding registers in a single peptide processed from myelin basic protein influences tolerance and susceptibility to autoimmunity
Rocco et al. Glatiramer acetate: a complex drug beyond biologics
Monneaux et al. Importance of spliceosomal RNP1 motif for intermolecular TB cell spreading and tolerance restoration in lupus
Wenhart et al. A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
Khalil et al. Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments
Myers et al. Peptide‐induced suppression of collagen‐induced arthritis in HLA–DR1 transgenic mice
Monneaux et al. Intramolecular T cell spreading in unprimed MRL/lpr mice: Importance of the U1‐70k protein sequence 131–151
US7867976B2 (en) Nogo epitopic fragments for modulating immune response
JP6536944B2 (ja) 自己免疫疾患の発症に関与する細胞を判定する方法及びその利用
Lee et al. Molecular mimicry in neurological disease: what is the evidence?
Im et al. Protective molecular mimicry in experimental myasthenia gravis
AU2002221775B2 (en) Methods for obtaining inhibitors of t-cell membrane protein (TIRC7) ligand binding and uses thereof
JP2024521926A (ja) 新規のペプチド模倣体およびそれらの使用
Liem et al. Vries-Bouwstra
Kovalchin et al. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response
Benson et al. Arthritis in space and time–To boldly go!
US11435345B2 (en) Detection and treatment of demyelinating diseases
Bhat et al. Myasthenia Gravis: Molecular Pathogenesis and Therapeutic Advances
Li Myelin basic protein autoantibodies
Deen et al. Predictors of Multiple Sclerosis Relapse Location

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted